The prospect of applying differentiation therapies to the treatment of acute myeloid leukemias (AMLs) is highlighted by the use of all-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL). Treatment with ATRA in combination with chemotherapy or arsenic trioxide results in cure in the majority of patients with either newly diagnosed or recurrent APL. 1 The effectiveness of ATRA is because of the induction of differentiation in the APL leukemic blasts and their conversion to a nonproliferative state. However, ATRA is largely ineffective at inducing differentiation in non-APL subtypes of AML, and differentiation therapies for these other subtypes have not been developed. Therefore, it is important to identify the cellular signaling pathways that are aberrantly activated and act to inhibit myeloid differentiation in AML cells.
Previous studies have shown that Src family kinases (SFKs) are overexpressed and/or hyperactivated in AML cell lines and primary cells. SFKs are non-receptor tyrosine kinases that have been implicated in a variety of physiological process, including proliferation, survival, differentiation and migration. In all nine different SFKs have been identified, although the expression in myeloid lineage cells appears more restricted to the SFKs Lyn, Fgr, Hck and c-Src. 2 To determine the role of SFKs in regulating myeloid differentiation, we previously employed the pan-SFK inhibitors PP1 and PP2. Pharmacological inhibition of SFKs using PP1 or PP2 was found to markedly enhance ATRAinduced myeloid differentiation of AML cell lines, as well as primary cells from a patient with non-APL AML. 3 These findings showed that SFKs act as negative regulators of ATRA-induced myeloid differentiation.
To understand the mechanism(s) whereby SFKs negatively regulate myeloid differentiation, in this report we sought to determine the target genes that are regulated by SFKs in myeloid lineage cells. To accomplish this, NB4 cells were treated for 10 h with vehicle alone, 0.01 mM ATRA alone, 10 mM PP2 alone or ATRA plus PP2, followed by microarray analysis using Affymetrix GeneChip Human Genome U133A 2.0 Array. Table 1 Tables 1 and 9, and Supplementary Tables 2 and 10 ).
Of particular interest were those comparisons that allowed us to identify SFK gene targets. SFK gene targets were identified by comparing the PP2 versus vehicle groups, as well as the ATRA plus PP2 versus ATRA groups. Comparison of PP2 versus vehicle groups identified 186 genes that were upregulated (X2-fold) in response to SFK inhibition and 78 that were downregulated (X2-fold) ( Table 1) . Highly similar numbers of upregulated and downregulated genes were detected when comparing ATRA plus PP2 versus ATRA (206 and 109, respectively). The identities of SFK target genes identified in these two different comparisons were also similar (compare Supplementary Tables 3 and 7, and  Supplementary Tables 4 and 8 ). Among the genes that were found to be dramatically upregulated following SFK inhibition (Supplementary Tables 3 and 7) were several encoding cytokines (IL-8, IL-1b and IL-16), chemokines (CXCL10, CCL4, CCL7 and CCL8) or proteins involved in cytokine or TNF signaling (IL-18 receptor accessory protein, IL-18 receptor 1, TNF alpha-induced protein 6 and IL-10 receptor alpha). SFK inhibition also led to marked upregulation of the genes encoding the adhesion proteins thrombospondin 1 and inter-cellular adhesion molecule-1 (ICAM-1). As these genes were upregulated following SFK inhibition, they represent genes that are negatively regulated by SFKs.
In addition to the genes mentioned above, another gene that was found to be negatively regulated by SFKs was the gene encoding early growth response-1 (Egr-1). An 8.5-fold upregulation of Egr-1 mRNA was observed when comparing the PP2 versus vehicle groups (Supplementary Table 3) , and a 13.1-fold upregulation was seen when comparing the ATRA plus PP2 versus ATRA groups (Supplementary Table 7 ). Egr-1 is a zinc finger transcription factor that has previously been implicated as playing a key role in myeloid differentiation. Expression of Egr-1 is induced during monocytic differentiation, and ectopic expression of Egr-1 promotes monocytic differentiation of HL-60 and M1 cells in the absence of a differentiation stimulus. [5] [6] [7] Further, ectopic expression of Egr-1 in M1 cells overcomes the blockade to differentiation imposed by c-Myc and E2F-1. 8 Our observation that SFKs negatively regulate the Egr-1 gene suggests a mechanism whereby hyperactivated or overexpressed SFKs may act to inhibit the differentiation of AML cells.
To verify that SFKs negatively regulate Egr-1 expression, we performed immunoblotting experiments following inhibition of Letters to the Editor the SFK enzymes ( Figure 1 ). NB4 cells were left untreated, or were treated for 2 h with ATRA alone, PP2 alone or ATRA plus PP2. In the absence of treatment, low levels of Egr-1 protein were detected. Interestingly, treatment with ATRA alone resulted in reduction in Egr-1 levels, consistent with a previous report that Egr-1 is associated with monocytic, but not granulocytic differentiation. 6, 7 By contrast, treatment with PP2 alone resulted in dramatic upregulation of Egr-1, supporting our contention that the Egr-1 gene is a negatively regulated target of SFKs. In Figure 2 we performed an immunoblotting time course of cells treated with PP2 alone. Induction of Egr-1 protein was detected as soon as 30-60 min after the addition of SFK inhibitor. Expression of Egr-1 peaked at around 4 h, but was maintained at above-basal levels at 48 h and beyond.
The rapid induction of Egr-1 protein following SFK inhibition suggested that SFKs may act directly to repress the Egr-1 gene. To determine whether SFKs directly repress the Egr-1 gene, we performed reverse transcription-polymerase chain reaction (RT-PCR) analysis of Egr-1 mRNA induction in the absence or presence of the protein synthesis inhibitor cycloheximide. As shown in Figure 3a , treatment of NB4 cells with PP2 alone resulted in increased expression of Egr-1 mRNA, relative to vehicle-treated cells. Cycloheximide, while blocking PP2 induction of Egr-1 protein (Figure 3b ), failed to block the induction of Egr-1 mRNA (Figure 3a) . This indicates that the induction of Egr-1 mRNA following SFK inhibition does not depend on the synthesis of new proteins. These results support the contention that SFKs directly regulate the expression of the Egr-1 gene through post-translational mechanisms.
In conclusion, in an effort to understand how SFK enzymes act to negatively regulate myeloid differentiation, we have used microarray studies to identify SFK gene targets. We have discovered that the gene encoding Egr-1, a key regulator of myeloid differentiation, is directly and negatively regulated by SFKs. Pharmacological inhibition of SFKs led to rapid induction of Egr-1 mRNA and protein. Collectively, these findings suggest that SFKs, which are frequently overexpressed and/or hyperactivated in AML, act, in part, to inhibit the differentiation of leukemic cells by repressing the expression of Egr-1.
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The authors declare no conflict of interest. Thus, if NF-kB and Wnt pathways are really controlled by common genes, drugs able to modulate one or both of these signals would represent innovative therapeutic tools in treatment of myeloproliferative disorders.
NF-kB is constitutively activated in acute myeloid leukemia, high-risk myelodysplastic syndromes and chronic myeloproliferative Ph-negative disorders. 2 Histone deacetylase inhibitors (HDACIs) seem to be able to interfere with the NF-kB pathway. 3 Currently available HDACIs include valproic acid, depsipeptide, LBH589, ITF2357 and vorinostat. Recently, oral formulation of vorinostat has been assessed in a phase-I trial, recruiting 41 patients with relapsed or refractory leukemia and myelodysplastic syndromes, with promising results. 4 Recently, in 41% of acute myeloid leukemia and myelodysplastic syndrome cases, malignant cells stained positively for b-catenin, with significant association between Wnt activation and M7 subtypes, deletion of chromosome 7 and complex karyotypes, conditions significantly associated with a poorer prognosis. 5 Thus, the possibility of using an HDACI for inhibiting NF-kB and/or Wnt in myeloid disorders would be an attractive therapeutic option.
On these bases, we assessed whether vorinostat would be really able to deregulate the NF-kB pathway in the M-07e megakaryoblastic cell line. These cells have already been employed as a model for chronic myeloid disorders and some of the apoptotic mechanisms in this line have been previously reported in the literature. 6 As electrophoretic mobility shift assay (EMSA) showed that vorinostat significantly reduced NF-kB DNA-binding activity, we also carried out gene-expression analyses to assess whether genes involved in the NF-kB and Wnt pathways were deregulated by the exposure to vorinostat.
Vorinostat was supplied by Merck Sharp and Dome (Rome, Italy), dissolved in DMSO as a 20-mM stock solution and diluted to the required concentrations with serum-free culture medium.
Megakaryoblastic M-07e cell line (DSMZ: German collection of microorganisms and cell cultures) was grown in RPMI-1640 medium (Gibco-Life Technologies, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum, 2-mmol/l L-glutamine and 1% gentamicin at 37 1C, 10 ng/ml recombinant human granulocyte-macrophage colony-stimulating factor (Novartis, Basel, Switzerland). Cell viability was determined by trypan-blue exclusion, and proliferative responses were assayed by a colorimetric test based on methyl thiazol tetrazolium bromide reduction. The extent of apoptosis was evaluated by Annexin Vfluorescein isothiocyanate staining and flow cytometry, as recommended by manufactures (Becton Dickinson, San Diego, CA, USA). After incubation with 50 mg/ml propidium iodide and 5 mg/ml of RNAase I (Roche, Indianapolis, IN, USA), cell-cycle analysis was carried out by FACSort flow cytometry (Becton Dickinson) and Cell Quest (Becton Dickinson) program was used to evaluate the cell-cycle distribution. EMSA was carried out as described previously. 7 For microarray analyses, each sample was hybridized on 4 Â 44K Whole Human Genome Microarray (Agilent Technologies, Palo Alto, CA, USA), and then scanned using a confocal laser scanner (Agilent Technologies). Fluorescence data were analysed using Feature Extraction Software v.9.1 (Agilent Technologies). Data coming from each scan (Log 10 treated per reference and Log 10 control per reference) were imported into the gene-expression analysis software Luminator (Rosetta Bio Software, Seattle, WA, USA). Two independent experiments were carried out. The same mRNAs used for microarray experiments have also been used for the real-time PCR quantitative assays, carried out using RT 2 Profiler PCR Arrays (SuperArray Bioscience Corporation, Frederick, MD, USA). Reported values represent the means± s.d. The significance of differences between experimental conditions was determined using the two-tailed Student's t-test. The level of significance was Po0.05.
To confirm the data already reported by our group 6 in this new experimental setting we performed proliferation assays by exposing M-07e cells to increasing drug concentrations (from 0.1 to 5 mM). These concentrations correspond to those measurable in the plasma of patients receiving a single oral administration of vorinostat, 400 mg after 3 h. As shown in Figure 1 , vorinostat significantly reduced the proliferation of M-07e cells, in a dose-and time-dependent manner.
To determine whether the anti-proliferative activity induced on M-07e cell line by vorinostat was caused by cell-cycle arrest and/or induction of programmed cell death, apoptosis was assessed using Annexin-V staining and flow-cytometry evaluation. For these experiments, cells were incubated with either medium or vorinostat (ranging from 0.1 to 5 mM) for 24 and 48 h. As shown in Figure 2 , significant differences in apoptosis were observed between untreated and treated cells. The pro-apoptotic effect started from a concentration of 1.5 mM after 24-h incubation. At higher concentrations and longer time exposure, the cytotoxicity was the more evident effect.
For the cell-cycle analysis, M-07e cells were incubated with sub-lethal concentrations of vorinostat (0.5 mM) for 24 h. At this concentration, vorinostat induced cell-cycle arrest in the G 1 phase.
In order to find whether vorinostat would inactivate NF-kB, the NF-kB DNA-binding activity was evaluated using EMSA. Untreated M-07e cells showed a partial constitutive activation
